Skip to main content
Caplight Logo









OneOme

OneOme

Private
Minneapolis, MinnesotaHealthcare & Life Scienceshttps://oneome.com

Last Round

VC Round

Oct 15, 2016

Momentum

Top 50%

of companies Caplight tracks

Company Overview

OneOme operates in Healthcare & Life Sciences and is based in Minneapolis, Minnesota. Its latest recorded funding round was a VC Round in October 2016.

OneOme is a biotechnology company that provides a pharmacogenomic and analytical platform designed to help doctors select medications to improve outcomes and reduce adverse drug reactions.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics, EHR & EMR

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

OneOme Comparables

Compare OneOme with similar companies based on industry and business-model similarity.

OneOme comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ActX, Inc.
86%
Admera Health
83%
Genomind
80%
Book a demo to see all comparables

For institutional investors. Book with your work email.

OneOme Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 15, 2016
SeedSep 23, 2014
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

OneOme Investors

Notable investors and investment history

OneOme investors
InvestorRounds
InvenshureVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 24, 2025

    Acquiring pharmacogenetics assets from defunct OneOme.

  • Nov 8, 2025

    Monthly visitors increased 50% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

OneOme Filings

Explore SEC and related filing metadata, where available.

OneOme filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about OneOme's valuation, stock price, and market status.

Is OneOme a public or private company?

OneOme is a private company.

What is the current stock price of OneOme?

OneOme is a private company, so its shares have no public market price. Caplight tracks OneOme's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is OneOme worth (valuation)?

Valuation information for OneOme is not publicly available.

Can I buy OneOme stock?

OneOme shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was OneOme's last funding round?

OneOme's most recent funding round was VC Round on October 15, 2016.

Who are the main investors in OneOme?

Key investors in OneOme include Invenshure.

Will OneOme IPO soon?

No public IPO plans have been announced for OneOme.

How can I track OneOme secondary market activity?

Caplight tracks bids, offers, and trades in OneOme's shares on secondary markets.

Firmographic Details

HeadquartersMinneapolis, Minnesota
Employee Range15
Year Founded2013
Last FundingOct 15, 2016

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?